1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Swedencare AB

Swedencare AB

19.26
SEK
+0.46
(+2.45%)
0.32EPS
78.82P/E
4.01BMarket Cap
Feb 11Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.31
0.5
0.77
1.08
1.26
1.61
2.76
6.88
11.87
14.73
15.93
16.81
16.65
Basic EPS, GAAP
0.05
0.12
0.14
0.22
0.3
0.38
0.38
0.49
0.61
0.37
0.62
0.35
0.32
Free Cash Flow per Basic Share
0.06
0.05
0.03
0.15
0.16
0.36
0.41
0.88
1.19
2.57
1.81
1.73
1.01
Dividend per Share
- -
0.03
- -
- -
- -
- -
0.13
0.15
0.2
0.22
0.23
0.25
0.53
Book Value per Share
0.07
0.17
0.72
0.94
1.25
1.66
8.79
20.48
47
45.4
50.56
41.7
44.41
Tangible Book Value per Share
0.07
0.16
0.08
0.3
0.61
1
2.02
-2.94
-5.72
-4.42
-2.96
-6.08
-5.17
Basic Weighted Avg Shares
77
55
70
79
79
79
87
112
155
159
159
160
160
Sales/Revenue/Turnover
24
27
54
85
99
127
240
770
1,843
2,338
2,530
2,683
2,661
Operating Margin (%)
18.85
31.8
21.65
25.61
28.85
29.04
17.12
8.39
6.52
7.63
8.77
5.09
5.64
Depreciation Expense
- -
- -
2
1
1
3
13
73
269
310
316
311
306
Net Income, GAAP
4
7
10
17
23
30
33
55
95
59
99
56
51
Effective Tax Rate (%)
23.56
22.58
17.63
20.5
19.83
18.47
16.03
4.01
- -
27.74
34.29
32.73
27.49
Profit Margin (%)
14.55
24.59
18.06
19.9
23.46
23.6
13.9
7.09
5.13
2.51
3.91
2.07
1.91
Working Capital
9
11
21
30
38
64
335
337
697
694
774
685
761
LT Debt
- -
- -
17
9
2
2
139
704
1,867
1,626
1,427
1,756
1,709
Total Equity
5
13
57
74
98
131
918
2,420
7,461
7,207
8,032
6,665
7,098
Return on Invested Capital (%)
- -
62.46
19.35
19.38
22.72
23.87
5.56
2.9
- -
1.36
1.59
1.03
1.2
Return on Capital (%)
- -
72.27
21
20.11
23.54
24.69
5.65
2.99
- -
1.38
1.66
1.06
1.31
Return on Common Equity (%)
- -
72.14
28
26
27.04
26.06
6.36
3.27
1.91
0.8
1.3
0.76
0.71

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
53
55
58
LT Borrowings
1,461
1,704
1,709
LT Finance Leases
295
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
160
160
160
Market Capitalization
6,138
3,860
4,012

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,103
1,151
1,194
Cash, Cash Equivalents & STI
103
95
85
Accounts Receivable, Net
289
295
299
Inventories
493
528
566
Total Current Liabilities
418
425
433
Payables & Accruals
- -
- -
- -
ST Debt
53
55
58
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
138.96%
72.57%
-17.02%
Free Cash Flow
100.28%
70.28%
-4.24%
Net Income, GAAP
32.08%
24.73%
-43.88%
Sales/Revenue/Turnover
69.17%
80.29%
6.04%
Total Cash Common Dividend
- -
32.86%
9.59%

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
599
632
644
665
2,530
2025
646
649
- -
685
2,683
2026
655
673
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.13
0.15
0.15
0.62
2025
0.15
-0.04
- -
0.1
0.35
2026
0.11
0.15
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.23
- -
- -
0.23
2025
- -
0.25
- -
- -
0.25
2026
- -
0.28
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Lars Håkan Lagerberg
Full Time Employees
613
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Medeon Science Park Malmö SN Sweden 205 12
IPO Date
Jun 14, 2016
Website
swedencare.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Swedencare AB (publ) (SECARE.ST) develops, manufactures and markets premium pet health products, with a focus on nutritional supplements, oral care, dermatology, joint support, digestive health and grooming solutions for dogs, cats and horses. The company offers a broad portfolio of branded products including ProDen PlaqueOff®, the original seaweed-based dental health solution; NaturVet® soft chews and supplements; Innovet science-based premium formulations; Pet MD® online-targeted supplements and topicals; Rx Vitamins®; nutravet®; Rileys® Organics; Healthy Breeds animal nutritional supplements, treats and grooming items; as well as offerings from NutriScience, Summit Veterinary Pharmaceuticals, Vet Worthy and Healthy Solutions for Pets; distributed through veterinarians, pet stores, pharmacies, e-commerce platforms such as Amazon, Chewy and zooplus, and direct-to-consumer channels. Founded in 2000 and headquartered in Malmö, Sweden, Swedencare operates globally across approximately 70 countries with subsidiaries and production facilities primarily in Europe and North America, targeting premium segments in the veterinary supplies and pharmaceuticals industry. Recent developments include the 2025 acquisitions of Summit Veterinary Pharmaceuticals in the UK, Pack Approved assets, NaturVet's Amazon account, and earlier brand purchases such as Riley's Organics, Vet Worthy and Healthy Solutions for Pets; a directed new share issue raising SEK 3.6 billion to finance expansions; investments in manufacturing capacity at Vetio facilities for soft chews, treats and liquids; and strengthened US market presence through Walmart store expansions and organizational enhancements in veterinary and e-commerce channels.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Q3 2026 Earnings Call Transcript

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Discusses CEO Retirement and Business Segment Performance Transcript

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    Swedencare AB (publ) (SWDCF) Q4 2025 Earnings Call Transcript